Mr Cyrus Aibara is incharge of the overall diabetes commercial and marketing operations in Sanofi India
The global healthcare industry and medical fraternity is alarmed at the rate at which the diabetic population has been increasing worldwide. Globally, more than 366 million people are living with diabetes and there are far more, who have not made it to the official records.
Data from the International Diabetes Federation shows that 80 percent of people with diabetes live in low-and middle-income countries. The disease is constantly in news as it is a huge and a growing problem in every country. In 2011, India had 61.3 million diabetic subjects and this number is projected to increase to 101.2 million by the year 2030.
One can make out the burden of diabetes in India by just looking at the total size of diabetes market, which is worth Rs450 crore. Sanofi, as a company is ranked number three in Indian diabetes market, and is positioned a shade behind Abbott and Sun Pharma. In our endeavor to become a 360 degree partner, we deliver the best-in-class complete and integrated solutions to diabetic patients, and we are the only company in diabetes arena to have a balanced portfolio of both oral and insulin medication supported by patient services.
Diabetes has become a major health problem in India. Organizations are working at breakneck speed to get the latest development to the market promising better medications, technologies, and improved insulin delivery devices. The recently launched reusable insulin pen 'ALLSTAR', from Sanofi is a testimony towards the same.
ALLSTAR is a custom made pen for diabetic patients in India. The pen will help improve both insulin initiation and compliance, and bring ease and reassurance to the lives of millions of Indian patients, giving them the convenience of international standards at an affordable price.